Clinical TrialMay 20, 2026, 08:02 AM
Gelteq Begins First Clinical Trial for Antiparasitic Drug
AI Summary
Gelteq Ltd. has commenced its first clinical trial for an antiparasitic drug candidate, marking its expansion into the veterinary pharmaceutical sector. This trial aims to support the company's planned FDA regulatory pathway for animal use, with a potential application targeted for later in 2026. The move reinforces the versatility of Gelteq® technology across human and animal health, positioning the company to participate in the growing global animal health market, estimated to exceed USD $78 billion in 2026. Gelteq is well-capitalized to pursue both pharmaceutical programs and its nutraceutical portfolio.
Key Highlights
- Gelteq commenced its first clinical trial for an antiparasitic drug candidate.
- The trial supports a planned FDA regulatory pathway for animal use.
- Company targets a potential FDA application later in 2026.
- This marks Gelteq's expansion into the veterinary pharmaceutical sector.
- The global animal health market is estimated to exceed USD $78 billion in 2026.
- Gelteq is well-positioned with sufficient capital from recent financing.
Price Impact
More from GELS